Drawing on patient research, UK prescribing trends and launch patterns observed in the United States, Simple Online Healthcare estimates oral GLP-1 treatments could reach 120,000-130,000 UK patients within the first three months of launch, with around 100,000 expected to be entirely new to obesity management medication
The development of stable, long-acting GLP-1RAs marks significant advancement, positioning these agents at the forefront of translational research across multiple disease domains
It is an autoimmune disease with other comorbidity diseases and an increased risk of other conditions which should be properly monitored and managed even if we are a very long way from that being the reality in the UK
Clinical evidence is developing, so check with your surgeon for specific guidance
For a medical treatment that can cause gastrointestinal side effects in up to 70 percent of users, accessible clinical support is not optional
DrSkin Med Spa in Gilbert, AZ, can assist with navigating insurance and exploring cost-saving options
